Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings Supplementary materials

This study was funded by G1 Therapeutics, Inc. L Lopez-Gonzalez and H Huang are employees of G1 Therapeutics, Inc. J Goldschmidt is an employee of The US Oncology Network, which received funding from G1 Therapeutics, Inc., for this work. A Monnette, P Shi and D Venkatasetty are employees of Ontada, which received funding from G1 Therapeutics, Inc., for this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing assistance was provided by Barbara Blaylock from Blaylock Health Economics LLC funded by G1 Therapeutics, Inc.